Aigen Investment Management LP Purchases Shares of 11,612 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Aigen Investment Management LP purchased a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,612 shares of the company’s stock, valued at approximately $465,000.

A number of other hedge funds also recently modified their holdings of the business. GAMMA Investing LLC raised its position in Ionis Pharmaceuticals by 83.9% during the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after purchasing an additional 303 shares during the last quarter. nVerses Capital LLC bought a new stake in Ionis Pharmaceuticals in the second quarter valued at approximately $29,000. Itau Unibanco Holding S.A. acquired a new stake in Ionis Pharmaceuticals during the 2nd quarter valued at approximately $37,000. Mather Group LLC. increased its position in Ionis Pharmaceuticals by 35.8% during the 2nd quarter. Mather Group LLC. now owns 911 shares of the company’s stock valued at $39,000 after purchasing an additional 240 shares during the period. Finally, Capital Performance Advisors LLP acquired a new position in shares of Ionis Pharmaceuticals in the 3rd quarter worth approximately $40,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ:IONS opened at $37.23 on Friday. The company has a market capitalization of $5.88 billion, a P/E ratio of -15.26 and a beta of 0.39. The company’s 50-day moving average is $39.87 and its 200 day moving average is $42.80. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $35.95 and a fifty-two week high of $54.44.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 1,194 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total value of $45,276.48. Following the sale, the executive vice president now directly owns 33,713 shares in the company, valued at $1,278,396.96. The trade was a 3.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Brett P. Monia sold 6,630 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $38.05, for a total value of $252,271.50. Following the transaction, the chief executive officer now directly owns 167,393 shares in the company, valued at $6,369,303.65. This represents a 3.81 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 8,197 shares of company stock valued at $315,310. Company insiders own 2.71% of the company’s stock.

Analyst Upgrades and Downgrades

IONS has been the topic of several research analyst reports. Leerink Partners upgraded Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the company from $53.00 to $62.00 in a research report on Wednesday, July 24th. TD Cowen increased their target price on shares of Ionis Pharmaceuticals from $54.00 to $59.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Leerink Partnrs raised shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 24th. Bank of America boosted their target price on Ionis Pharmaceuticals from $67.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, Guggenheim dropped their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $60.65.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.